Drug Type Hormone |
Synonyms |
Target |
Mechanism AMYR agonists(Amylin receptor agonists), INSR agonists(Insulin receptor agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 1 | Phase 2 | - | - |
Not Applicable | - | (bczldziuol) = pghmzgidkn pqnowlcspn (qydokmvanj ) View more | - | 12 Jan 2023 | |||
(bczldziuol) = hbbrujmqnd pqnowlcspn (qydokmvanj ) View more | |||||||
Not Applicable | 16 | qxhmbwtwru(bpghjqazhp) = more adverse events (AEs) occurred with ADO09 (22 vs. 10), most AEs were mild and of gastro-intestinal nature (nausea, decreased appetite) lbileljruv (acjzgzrvkv ) View more | Positive | 01 Jun 2021 | |||
Not Applicable | 21 | osntnrapoz(mmkgxwbmru) = more gastrointestinal adverse events (24 vs. 6) observed with ADO09, consistent with typical effect of PRAM yrbxkmmvex (kxayzpsrci ) | Positive | 01 Jun 2020 | |||
Not Applicable | 24 | (zibwbyxqcf) = 3 with ADO09, 2 with Ins&Pram hzepknsuny (kgudazikpx ) View more | Positive | 18 Sep 2019 | |||